Baird Maintains Outperform on Ocular Therapeutix, Raises Price Target to $30
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and raises the price target from $24 to $30.
Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and raises the price target from $24 to $30.